Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gabizon

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2T Safra, F Muggia, S Jeffers, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2016
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in ChemoradiotherapyXi Tian, Samuel B Warner, Kyle T Wagner, et al.
Cancer Medicine|July 15, 2015
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patientsTalia Golan, Tal Grenader, Patricia Ohana, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Clinical studies of liposome-encapsulated doxorubicinA Gabizon, R Isacson, E Libson, et al.
Nanotheranostics|September 15, 2022
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma modelMd Rakibul Islam, Jalpa Patel, Patricia Ines Back, et al.
International Journal of Nanomedicine|December 13, 2018
Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenograftsEsben Christensen, Jonas R Henriksen, Jesper T Jørgensen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 1991
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyD Papahadjopoulos, T M Allen, A Gabizon, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 27, 2017
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronateRobin Rajan, Manoj K Sabnani, Vikram Mavinkurve, et al.
Frontiers in Oncology|December 12, 2018
Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical ExperienceEsther Tahover, Rachel Bar-Shalom, Eli Sapir, et al.
Biomolecules|September 28, 2023
Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma ModelMd Rakibul Islam, Jalpa Patel, Patricia Ines Back, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2T Safra, F Muggia, S Jeffers, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2016
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in ChemoradiotherapyXi Tian, Samuel B Warner, Kyle T Wagner, et al.
Cancer Medicine|July 15, 2015
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patientsTalia Golan, Tal Grenader, Patricia Ohana, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Clinical studies of liposome-encapsulated doxorubicinA Gabizon, R Isacson, E Libson, et al.
Nanotheranostics|September 15, 2022
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma modelMd Rakibul Islam, Jalpa Patel, Patricia Ines Back, et al.
International Journal of Nanomedicine|December 13, 2018
Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenograftsEsben Christensen, Jonas R Henriksen, Jesper T Jørgensen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 1991
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyD Papahadjopoulos, T M Allen, A Gabizon, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 27, 2017
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronateRobin Rajan, Manoj K Sabnani, Vikram Mavinkurve, et al.
Frontiers in Oncology|December 12, 2018
Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical ExperienceEsther Tahover, Rachel Bar-Shalom, Eli Sapir, et al.
Biomolecules|September 28, 2023
Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma ModelMd Rakibul Islam, Jalpa Patel, Patricia Ines Back, et al.
Pageof 9